Beyond the Beach: RuffleButts Leads the Way in Sun Protection With UPF 50+ Swim & Activewear
With the launch of their new UPF 50+ activewear line, RuffleButts is setting the standard for sun protection in the children's swim & apparel markets.
DALLAS, TEXAS / ACCESS Newswire / February 4, 2025 / RuffleButts + RuggedButts, the beloved premium children's apparel brand known for known for lasting quality, playful prints, and family-matching collections for life's special moments, is making waves in the industry by leading the charge in UPF 50+ sun protection. As a trusted name in children's swimwear, RuffleButts has long been a go-to for parents seeking stylish, high-quality swimsuits that offer superior sun safety. Now, the brand is expanding its commitment to sun protection by introducing UPF 50+ fabrics to its activewear line.New Activewear Front and Detail shot of new activewear dress.
RuffleButts' best-selling swimwear features a variety of UPF 50+ options designed for the entire family. Featuring playful prints, fun styles, and bright colors both kids and parents love with a lasting quality that resists pilling, snagging, and fading wash after wash, the brand ensures that families can enjoy fun in the sun without compromising on style or safety.
With the new addition of UPF 50+ activewear, RuffleButts is taking sun protection beyond the beach. The new activewear line features lightweight, breathable, and protective fabrics perfect for playdates, outdoor adventures, and everyday wear.
'Our brand has a strong reputation built on quality and stylish playful designs,' said Alicia Dewar, VP of Merchandise, Planning, and Design. 'With our UPF 50+ swimwear already a customer favorite, it was a natural expansion to incorporate this same protection into our new activewear line. We are thrilled that our customers will have additional sun protection not only at the pool or beach but also in their daily active lifestyle.'
As families continue to prioritize sun protection, RuffleButts + RuggedButts remains at the forefront of the industry, providing innovative designs that blend fashion, fun, and function. With their latest UPF 50+ offerings, the brand continues to set the standard for stylish, sun-protective swim & activewear for your little ones.
For more information, visit www.rufflebutts.com or www.ruggedbutts.com and explore the latest in sun-safe swimwear and activewear.
About RuffleButts + RuggedButts
RuffleButts + RuggedButts is a digitally native premium children's apparel company founded in 2007 with a ruffle bloomer that has now grown to a full assortment of premium children's apparel. Known for lasting quality, playful prints, and family-matching collections for life's special moments, RuffleButts has quickly grown to annual revenue exceeding $40M. Our products can be found online at Rufflebutts.com, Ruggedbutts.com, Amazon, select premium retailers such as Nordstrom, Neiman Marcus and hundreds of specialty retail locations around the globe. RuffleButts has been a Summit Park holding since 2020.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
5 hours ago
- Miami Herald
Crazy Discount Codes App Helps Shoppers Save Big with Curated Retail Deals
Mobile app simplifies deal hunting by delivering real-time discounts from top retailers-all in one easy-to-use platform. ATLANTA, GA / ACCESS Newswire / June 13, 2025 / Shoppers looking to stretch their dollars now have a powerful new tool: Crazy Discount Codes, a mobile app that delivers the best retail discounts directly to their fingertips. The app curates real-time deals from top brands and retailers, eliminating the need to search multiple sites or clip coupons. Created with convenience in mind, Crazy Discount Codes offers an all-in-one destination for discovering verified deals across fashion, electronics, home essentials, and more. Users can effortlessly browse time-sensitive promotions from well-known stores-all within a clean, user-friendly interface. "I built this app because I know how frustrating it is to miss out on deals or waste time looking for discounts," said Elpagnier Williams, founder of Crazy Discount Codes. "This app brings together the best offers and saves people both time and money." Now available on the App Store and Google Play, Crazy Discount Codes is already gaining traction among everyday shoppers and savvy savers alike. Whether you're browsing for essentials or exploring weekend sales, this app ensures you never miss a chance to save. About Crazy Discount Codes Crazy Discount Codes is a mobile savings platform that curates the latest retail discounts from major brands. Designed for smart shoppers, the app delivers verified deals in a clean, easy-to-use mobile experience. Learn more and download the app: Download on the App StoreDownload on Google Play Contact Information Elpagnier Williams Founder, Crazy Discount Codesads@ SOURCE: Crazy Discount Codes press release
Miami Herald
5 hours ago
- Miami Herald
GA-ASI Adds Saab Airborne Early Warning Capability to MQ-9B
New Capability Will Transform Airborne Early Warning Access and Affordability for MQ-9B Customers SAN DIEGO, CA / ACCESS Newswire / June 16, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is partnering with Saab to develop Airborne Early Warning and Control (AEW&C) capability for its line of MQ-9B Remotely Piloted Aircraft, which includes the SkyGuardian® and SeaGuardian® models, the United Kingdom's Protector, and the new MQ-9B STOL (Short Takeoff and Landing) model currently in development. GA-ASI plans to fly AEW on MQ-9B in 2026. "High and low-tech air threats both pose major challenges to global air forces," said GA-ASI President David R. Alexander. "We're developing an affordable AEW solution in cooperation with Saab, the leading provider of AEW&C systems, that will transform our customers' operations against both sophisticated cruise missiles and simple but dangerous drone swarms. We're also making AEW capability possible in areas it doesn't exist today, such as from some navy warships at sea." GA-ASI will pair Saab's AEW sensors with the world's longest-range, highest-endurance unmanned aircraft system (UAS), the MQ-9B. At sea or over land, the AEW mission package on MQ-9B will put air dominance within reach at a lower cost than legacy platforms. The MQ-9B AEW solution will offer critical aloft sensing to defend against tactical air, guided missiles, drones, and other threats at a fraction of the cost of manned platforms. Operational availability for medium-altitude long-endurance UAS is the highest of any military aircraft, and as an unmanned platform, its aircrew are not put into harm's way. AEW for MQ-9B will augment existing AEW fleets by extending their effective ranges. It also gives air forces that need AEW, but lack legacy platforms, a powerful and affordable means to counter threats. GA-ASI and Saab's AEW offering will span a wide range of applications, including early detection and warning; long-range detection and tracking; simultaneous target tracking and flexible combat system integration, all over line-of-sight and SATCOM connectivity. MQ-9B is the world's most advanced medium-altitude, long-endurance UAS. GA-ASI has MQ-9B orders from the United Kingdom, Belgium, Canada, Poland, Japan, Taiwan, India, and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also supported various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, RIMPAC, and Group Sail. About GA-ASI General Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 8 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle® 25M, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike. For more information, visit Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries. # # # Contact Information GA-ASI Media Relations asi-mediarelations@ 524-8101 SOURCE: General Atomics Aeronautical Systems, Inc. press release
Miami Herald
5 hours ago
- Miami Herald
Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice
Findings highlight the advantages of Adolore's approach for the delivery of proprietary gene therapy directly to specialized pain-sensing peripheral nerves (nociceptors) that mediates profound analgesia with the potential to address the great unmet need for non-opioid chronic pain therapies Data further supports the clinical-translational value of Adolore's proprietary non-opioid analgesics for treating chronic non-cancer pain These data support the Company's continuing efforts to progress with IND-enabling studies of ADB-102 gene therapy for the treatment of osteoarthritis (OA) chronic knee pain. DELRAY BEACH, FL / ACCESS Newswire / June 15, 2025 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford Levitt, MD, Clinical Professor at the University of Miami, Principal Investigator and Program Director of the NIH, NINDS, HEAL Award supporting ADB-102 development for the treatment of chronic knee pain due to OA, and Founder & Executive Chairman of Adolore BioTherapeutics, published biosafety and efficacy data from preclinical studies of Adolore's gene therapy expressing a human carbonic anhydrase-8 variant peptide (CA8*). In model systems, replication-defective, disease-free, herpes simplex virus (rdHSV) gene therapy expressing an analgesic carbonic anhydrase-8 (CA8*) peptide variant corrects somatosensory hyperexcitability by activating Kv7 voltage-gated potassium channels, produces profound, long-lasting analgesia and treats chronic pain from knee OA. In these studies, we provide the first non-Good Laboratory Practices (GLP) biosafety, efficacy, biodistribution, shedding, and histopathology examination of this rdHSV-CA8* via the intra-articular knee route of administration. Naive mice were examined for clinical safety, distribution of virus across all major tissues, knee histopathology, and analgesic efficacy. We observed no signs of persistent toxicity or histopathology, viral genomes remained where they were injected, and there was no evidence of shedding. Profound analgesia persisted for >6 months without functional impairments. These initial biosafety and efficacy data support further development of rdHSV-CA8* for treating chronic knee pain due to moderate-to-severe OA. Dr. Levitt, commented, "Kv7 voltage-gated potassium channel activators, like rdHSV-CA8* open these channels and hyperpolarize nociceptors making them less excitable to produce profound analgesia. Kv7 activators are well-known to produce potent non-opioid-based analgesia in many human chronic pain conditions. While Kv7 openers are no longer available due to off-target adverse events related to systemic administration, they have been successfully translated from animal models to human chronic pain conditions. Bolstered by our substantial body of published data, we continue to develop our innovative approach to address the significant serious unmet need for safe and effective locally acting pain therapies to replace opioids. Our preclinical data strongly support continued preclinical development toward an IND and clinical studies of ADB-102." The Company's lead development program for the treatment of chronic pain in knee osteoarthritis is fully funded by a UG3/UH3 grant awarded to the University of Miami by NIH/NINDS HEAL program to support all formal pre-clinical GLP/GMP/GCP development work through a first-in-human study of ADLR-1l01 in patients expected to commence in 2026. 1 Levitt et al., Biosafety and efficacy of Kv7 activating rdHSV-CA8* analgesic gene therapy for chronic pain via the intraarticular route in mice, Molecular Therapy (2025), About Carbonic Anhydrase-8 (CA8*) Gene Therapy CA8* (variants of naturally occurring human carbonic anhydrase-8 analgesic peptides) gene therapies are a novel class of neuronal calcium channel inhibitors that activate Kv7 voltage-gated potassium channels and are administered locally and long-acting. Oral small molecule pain therapeutics that activate Kv7 voltage-gated potassium channels demonstrated proven analgesic efficacy before they were removed from the market due to severe adverse events related to systemic exposure and their metabolism. CA8* gene therapy provides versatile dosing regimens and routes of administration, including intra-articular, intra-neuronal (nerve block), and intradermal injection. This non-opioid CA8* mechanism-of-action addresses neuropathic, inflammatory, and nociceptive pain, which applies to a broad range of chronic pain indications and neurological disorders. These conditions include osteoarthritis, lower back, and cancer pain; diabetes and other forms of peripheral neuropathy; as well as rare pain conditions such as erythromelalgia, a heritable chronic pain condition and epilepsy and hearing loss. About Adolore BioTherapeutics, Inc. Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for treating chronic pain using a revolutionary intra-cellular replication-defective HSV (rdHSV) drug delivery platform that is disease-free, non-toxic, and permits localized peripheral nervous system delivery of proprietary biotherapeutics. This rdHSV gene therapy technology incorporates an established re-dosing strategy and an excellent safety profile. HSV vectors are known for their stability and prolonged gene expression, providing an excellent basis for the long- term treatment of chronic pain conditions and neurological disorders. Our best-in-class CA8* programs are long-acting, locally administered gene therapies that are opioid-free Disease-Modifying Anti-Pain therapies (DMAPs) designed to treat many forms of chronic pain, epilepsy and hearing loss. Leveraging its innovative gene therapy vectors expressing CA8* analgesic peptides (ADLR-1001), Adolore is currently advancing two preclinical development programs: ADB-101 for the treatment of patients' chronic pain caused by erythromelalgia, an orphan disease, and ADB-102, their lead program for the treatment of patients with chronic pain caused by knee OA. Based on substantial compelling preclinical data generated to date, the Company is progressing these programs toward IND filings and first-in-human clinical studies. Adolore has two additional programs: ADB-104 for Drug-Resistant Refractory Focal Epilepsy and ADB-105 for Acute Severe Hearing Loss. For more information, visit Forward-Looking Statements To the extent, this announcement contains information and statements that are not historical, they are considered forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words "believe," "expect," "anticipate," "intend," "estimate," "project," "will," "should," "may," "plan," "intend," "assume" and other expressions which predict or indicate future events and trends and which do not relate to historical matters. You should not rely on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, some of which are beyond the control of the Company. These risks and uncertainties include but are not limited to those associated with drug development. These risks, uncertainties, and other factors may cause the actual results, performance, or achievements of the Company to be materially different from the anticipated future results, performance, or achievements expressed or implied by the forward- looking statements. Investor Relations Contact Paul Barone (215)622-4542pbarone@ SOURCE: Adolore Biotherapeutics, Inc.
